We are studying a new treatment, APL-101, for patients with advanced solid tumors, including non-small cell lung cancer with specific genetic mutations. The trial aims to assess its safety and effectiveness, as well as find the best dose.
Health conditions and diseases that the clinical trial is designed to study and treat.
Non-Small Cell Lung Cancer (NSCLC) is a type of lung cancer that is more common than small cell lung cancer. It can develop in different parts of the lungs and may cause symptoms like persistent cough, chest pain, and difficulty breathing.
A central nervous system neoplasm is an abnormal growth of cells in the brain or spinal cord, which can be benign or malignant. Symptoms may include headaches, seizures, and neurological deficits.
Solid tumors are abnormal masses of tissue that can occur in various organs, including the lungs, breast, and brain. They can be benign or malignant and may cause various symptoms depending on their location.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
